Clinical Trial Update: Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE® [Phase 2]

View source ↗

Summary

Phase II trial of IMVAMUNE to assess safety and immunogenicity for smallpox has completed. Results were posted on December 11, 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smallpox

Drugs mentioned

• IMVAMUNE (Modified Vaccinia Ankara (MVA))

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Smallpox | Phase 2 | Status: COMPLETED | Results posted: 2015-12-11